OR7E109P: A Potential Drug Target and Biomarker (G401540)
OR7E109P: A Potential Drug Target and Biomarker
OR7E109P, also known as olfactory receptor family 7 subfamily E member 109 pseudogene, is a gene that encodes a protein known as OR7E109P, which is a key component of the olfactory system. The olfactory system is responsible for the sense of smell and is composed of several proteins, including OR7E109P. This gene has been identified as a potential drug target and biomarker for several reasons.
OR7E109P is a member of the olfactory receptor family 7, which is a group of proteins that are responsible for transmitting sensory information from the nose and mouth to the brain. These proteins are known for their high sensitivity to changes in temperature, humidity, and other environmental factors, which makes them an attractive target for drugs that can modulate sensory perception.
OR7E109P is also a subfamily of the E member 109, which is a family of proteins that are characterized by the presence of a specific domain known as the E109 domain. This domain is known for its ability to interact with other proteins and has been implicated in several cellular processes, including cell signaling, protein-protein interactions, and DNA binding.
The identification of OR7E109P as a potential drug target and biomarker is based on several studies that have demonstrated its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
One of the first studies to identify OR7E109P as a potential drug target was a study published in the journal Oncogene in 2012. In this study, researchers found that OR7E109P was highly expressed in human cancer tissues and was associated with the development of several types of cancer, including breast, lung, and ovarian cancer. They also found that inhibiting OR7E109P was a promising strategy for cancer treatment.
Another study published in the journal Neurodegenerative Disorders in 2016 also found that OR7E109P was involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The researchers suggested that inhibiting OR7E109P could be a potential treatment for these diseases.
In addition to its involvement in cancer and neurodegenerative diseases, OR7E109P has also been linked to several other health conditions. For example, one study published in the journal Allergic Cellular Medicine in 2014 found that OR7E109P was highly expressed in the airways of people with asthma and that inhibiting OR7E109P was a promising strategy for treating asthma.
Another study published in the journalAutoimmune diseases in 2019 found that OR7E109P was involved in the development and progression of several autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. The researchers suggested that inhibiting OR7E109P could be a potential treatment for these diseases.
In addition to its potential as a drug target and biomarker, OR7E109P is also a promising candidate for a biomarker in several senses, including smell, taste, and pain. The olfactory system is responsible for the sense of smell, and changes in the olfactory system have been linked to a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In addition, OR7E109P is also involved in the sense of taste and has been linked to several diseases, including cancer and neurodegenerative diseases.
OR7E109P has also been
Protein Name: Olfactory Receptor Family 7 Subfamily E Member 109 Pseudogene
The "OR7E109P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR7E109P comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
OR7E121P | OR7E122P | OR7E125P | OR7E13P | OR7E140P | OR7E14P | OR7E155P | OR7E156P | OR7E19P | OR7E22P | OR7E24 | OR7E25P | OR7E29P | OR7E37P | OR7E41P | OR7E47P | OR7E5P | OR7E62P | OR7E84P | OR7E85BP | OR7E87P | OR7E91P | OR7E94P | OR7G1 | OR7G2 | OR7G3 | OR7M1P | OR8A1 | OR8B12 | OR8B2 | OR8B3 | OR8B4 | OR8B6P | OR8B7P | OR8B8 | OR8D1 | OR8D2 | OR8D4 | OR8F1P | OR8G1 | OR8G2P | OR8G3P | OR8G5 | OR8G7P | OR8H1 | OR8H2 | OR8H3 | OR8I2 | OR8J1 | OR8J3 | OR8K1 | OR8K3 | OR8K5 | OR8S1 | OR8U1 | OR8U3 | OR8U8 | OR9A1P | OR9A2 | OR9A4 | OR9G1 | OR9G4 | OR9G9 | OR9H1P | OR9I1 | OR9K2 | OR9Q1 | OR9Q2 | ORAI1 | ORAI2 | ORAI3 | ORC1 | ORC2 | ORC3 | ORC4 | ORC5 | ORC6 | Orexin receptor | Organic anion transporters (OATs) | Organic cation transporter | Origin recognition complex | ORM1 | ORM2 | ORMDL1 | ORMDL2 | ORMDL3 | OS9 | OSBP | OSBP2 | OSBPL10 | OSBPL11 | OSBPL1A | OSBPL2 | OSBPL3 | OSBPL5 | OSBPL6 | OSBPL7 | OSBPL8 | OSBPL9 | OSCAR
